Comparison of plasminogen activator inhibitor-1 levels in chronic hepatitis B patients with hepatic cirrhosis and without hepatic cirrhosis

Andhika Kusuma Hamdany; Muhammad Luthfi Parewangi; Sahyuddin Saleh; Syakib Bakri; Fardah Akil; Satriawan Abadi; Arifin Seweng

doi:10.3889/oamjms.2022.10439

Authors

Andhika Kusuma Hamdany Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Muhammad Luthfi Parewangi Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Sahyuddin Saleh Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Syakib Bakri Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Fardah Akil Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Satriawan Abadi Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Arifin Seweng Department of Biostatistics, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.10439

Keywords:

Chronic hepatitis B, Hepatic cirrhosis, Plasminogen activator inhibitor-1

Abstract

Introduction: One of the hepatic cirrhosis manifestations is bleeding disorders. Among all the substance that plays a pivotal role in maintaining the balance between thrombosis and thrombolysis is PAI-1, synthesized by hepatocytes. The dynamics of increase and decrease of PAI-1 is a natural response to the ongoing hepatic cirrhosis, but may not be seen in non-hepatic cirrhosis. PAI-1 levels also depends on the stage of fibrosis. Several conditions may interfere with PAI-1 levels including age, body mass index, and gender

Objectives: This study aims to find out the comparison of PAI-1 levels in hepatitis B patients with hepatic cirrhosis and without hepatic cirrhosis and to compare it with every stage of hepatic cirrhosis.

Patients and Methods: This study is an observational analytical study with a cross-sectional approach conducted at Wahidin Sudirohusodo hospitals, Makassar. Subjects are chronic hepatitis B patients with and without hepatic cirrhosis which meet inclusion criteria. Serum PAI-1 levels were measured by using Bender MedSystems human plasminogen activator inhibitor-1 ELISA kit (BMS2033) and using the ELISA technique. Statistical analysis was performed using the Kolmogorov Smirnov normality test as well as the Mann-Whitney method. Statistical results are considered significant if the p-value <0.05.

Results: The research was conducted on 60 subjects who meet inclusion criteria, consisting of 33 men and 27 women. There were 16 patients with hepatic cirrhosis. Levels of PAI-1 in hepatic cirrhosis was significantly different which lower than non-hepatic cirrhosis patient (0.43 ng/mL Vs 1.11 ng/mL, p=0.024). By staging of hepatic fibrosis, stage F2 hepatic fibrosis had the highest levels of PAI-1, in contrast with end-stage hepatic fibrosis which had the lowest levels.

Conclusion: Levels of PAI-1 fluctuate through different stages of hepatic fibrosis. The significant difference in PAI-1 levels in hepatic cirrhosis and non-hepatic cirrhosis demonstrates a correlation between PAI-1 and hepatic cirrhosis

Keywords: Chronic hepatitis B, Hepatic cirrhosis, Plasminogen Activator Inhibitor-1

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Allison MG, Shanholtz CB, Sachdeva A. Hematological issues in liver disease. Crit Care Clin. 2016;32(3):385-96. https://doi.org/10.1016/j.ccc.2016.03.004 PMid:27339678 DOI: https://doi.org/10.1016/j.ccc.2016.03.004

Arteel GE. New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury. J Gastroenterol Hepatol. 2008;23(Suppl 1):S54-9. https://doi.org/10.1111/j.1440-1746.2007.05285.x PMid:18336665 DOI: https://doi.org/10.1111/j.1440-1746.2007.05285.x

Flevaris P, Vaughan D. The role of plasminogen activator inhibitor Type-1 in fibrosis. Semin Thromb Hemost. 2017;43(2):169-77. https://doi.org/10.1055/s-0036-1586228 PMid:27556351 DOI: https://doi.org/10.1055/s-0036-1586228

Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2(7):163-86. https://doi.org/10.20517/2394-5079.2016.05 PMid:28042609 DOI: https://doi.org/10.20517/2394-5079.2016.05

MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5(5):a021410. https://doi.org/10.1101/cshperspect.a021410 PMid:25934461 DOI: https://doi.org/10.1101/cshperspect.a021410

Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: Natural history and treatment. Semin Liver Dis. 2006;26(2):142-52. https://doi.org/10.1055/s-2006-939752 PMid:16673292 DOI: https://doi.org/10.1055/s-2006-939752

Smith A, Baumgartner K, Bositis C. Cirrhosis: Diagnosis and management. Am Fam Physician. 2019;100(12):759-70. PMid:31845776

Wiegand J, Berg T. The etiology, diagnosis, and prevention of liver cirrhosis. Dtsch Arztebl Int. 2013;110(6):85-91. https://doi.org/10.3238/arztebl.2013.0085 PMid:23451000 DOI: https://doi.org/10.3238/arztebl.2013.0085

AbdulHameed MD, Tawa GJ, Kumar K, Ippolito DL, Lewis JA, Stallings JD, et al. Systems level analysis and identification of pathways and networks associated with liver fibrosis. PLoS One. 2014;9(11):e112193. https://doi.org/10.1371/journal.pone.0112193 PMid:25380136 DOI: https://doi.org/10.1371/journal.pone.0112193

Divella R, Mazzocca A, Gadaleta C, Simone G, Paradiso A, Quaranta M, et al. Influence of plasminogen activator inhibitor-1 (SERPINE1) 4G/5G polymorphism on circulating SERPINE-1 antigen expression in HCC associated with viral infection. Cancer Genomics Proteomics. 2012;9(4):193-8. PMid:22798504

Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001;121(1):131-9. https://doi.org/10.1053/gast.2001.25481 PMid:11438502 DOI: https://doi.org/10.1053/gast.2001.25481

Yildiz SY, Kuru P, Oner ET, Agirbasli M. Functional stability of plasminogen activator inhibitor-1. ScientificWorldJournal. 2014;2014:8582983. https://doi.org/10.1155/2014/858293 PMid:25386620 DOI: https://doi.org/10.1155/2014/858293

Noguchi R, Kaji K, Namisaki T, Moriya K, Kawaratani H, Kitade M, et al. Novel oral plasminogen activator inhibitor.1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats. Mol Med Rep. 2020;22(4):2948-56. https://doi.org/10.3892/mmr.2020.11360 PMid:32945412 DOI: https://doi.org/10.3892/mmr.2020.11360

Kareem WA, Abdullah BH, Waheed HJ. Estimation of plasminogen activator inhibitor-1 and some biochemical markers in a sample of Iraqi patients with liver cirrhosis. Syst Rev Pharm. 2021;12(3):96-9. https://doi.org/10.31838/srp.2021.3.17

Beier JI, Arteel GE. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood). 2012;237(1):1-9. https://doi.org/10.1258/ebm.2011.011255 PMid:22238286 DOI: https://doi.org/10.1258/ebm.2011.011255

Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease. Clin Liver Dis. 2009;13(1):21-31. https://doi.org/10.1016/j.cld.2008.09.008 PMid:19150306 DOI: https://doi.org/10.1016/j.cld.2008.09.008

Leebeek FW, Rijken DC. The fibrinolytic status in liver diseases. Semin Thromb Hemost. 2015;41(5):474-80. https://doi.org/10.1055/s-0035-1550437 PMid:26049070 DOI: https://doi.org/10.1055/s-0035-1550437

Von Montfort C, Beier JI, Kaiser JP, Guo L, Joshi-Barve S, Pritchard MT, et al. PAI-1 plays a protective role in CCl4-induced hepatic fibrosis in mice: Role of hepatocyte division. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):657-66. https://doi.org/10.1152/ajpgi.00107.2009 PMid:20203062 DOI: https://doi.org/10.1152/ajpgi.00107.2009

Nam D, Seong HC, Hahn YS. Plasminogen activator inhibitor-1 and oncogenesis in the liver disease. J Cell Signal. 2021;2(3):221-7. https://doi.org/10.33696/signaling.2.054 PMid:34671766 DOI: https://doi.org/10.33696/Signaling.2.054

Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis asish. J Cell Physiol. 2012;227(2):493-707. https://doi.org/10.1002/jcp.22783 PMid:21465481 DOI: https://doi.org/10.1002/jcp.22783

Yousuf SD, Ganie MA, Jeelani S, Mudassar S, Shah ZA, Zargar MA, et al. Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 and factor VIII among women with polycystic ovary syndrome: An observational pilot study. Indian J Med Res. 2018;148(Suppl):S151-5. https://doi.org/10.4103/ijmr.IJMR_1899_17 PMid:30964093

Eren M, Boe AE, Kiyachko EA, Vaughan DE. Role of plasminogen activator inhibitor-1 in senescence and aging. Semin Thromb Hemost. 2014;40(6):645-51. https://doi.org/10.1055/s-0034-1387883 PMid:25173500 DOI: https://doi.org/10.1055/s-0034-1387883

Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Circulation. 2003;107(3):398-404. https://doi.org/10.1161/01.CIR.0000052617.91920.FD PMid:12551862 DOI: https://doi.org/10.1161/01.CIR.0000052617.91920.FD